Related Experiment Video
Updated: Jun 15, 2026
03:50
Acupoint Application Combined with Acupoint Massage for Treating Constipation in a Patient with Chronic Obstructive Pulmonary Disease
Published on: August 18, 2023
Managing opioid-induced constipation in advanced illness: focus on methylnaltrexone bromide
Katri Elina Clemens1, Eberhard Klaschik
1Department of Science and Research, Centre for Palliative Medicine, University of Bonn, Germany;
Therapeutics and Clinical Risk Management
|March 18, 2010
Summary
Opioid-induced constipation is a significant issue in palliative care. Methylnaltrexone bromide offers a potential treatment option for patients unresponsive to standard laxatives.
Area of Science:
- Palliative Care Medicine
- Gastroenterology
Background:
- Constipation is a prevalent and distressing symptom in palliative care patients.
- Uncertainty exists regarding optimal management strategies and clinical practices for constipation in this population.
Purpose of the Study:
- To evaluate current therapy guideline recommendations for managing opioid-induced constipation (OIC) in palliative care.
- To specifically examine the role of methylnaltrexone bromide in OIC management.
Main Methods:
- Review of current literature on opioid-induced gastrointestinal disorders in advanced illness.
- Analysis of information regarding the opioid antagonist methylnaltrexone.
- Discussion of definitions, causes, and pathophysiology of OIC.
Main Results:
- Knowledge of OIC definitions, causes, and pathophysiology is crucial for effective treatment.
- Diagnosis and therapy should be guided by clinical investigation findings.
- Methylnaltrexone bromide is a potential therapeutic option for OIC refractory to oral laxatives.
Conclusions:
- Opioid-induced constipation presents a therapeutic challenge in advanced illness.
- Methylnaltrexone bromide may be a valuable option for palliative care patients with OIC who have not responded to conventional oral laxative treatment.
Related Concept Videos
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:17Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
01:21Drugs for Treatment of Constipation-Predominant IBS
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
01:15Opioid Analgesics: Synthetic and Semisynthetic Opioids
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
01:30Irritable Bowel Syndrome III: Medical and Nursing Management
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
01:25Analgesia and Pain Management
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...